Adenocarcinoma of the endometrium treated with combined irradiation and surgery: Study of 437 patients

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 1, 2001, Pages 81-97

  Mutic, Sasa ^a   Low, Daniel A ^a   Klein, Eric E ^a   Dempsey, James F ^a   Purdy, James A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Endometrial carcinoma; Radiotherapy; Risk factors; Surgery; Survival

Indexed keywords

HISTOLOGY; PATHOLOGY; PATIENT TREATMENT; RADIOTHERAPY; SURGERY; TOXICITY; TUMORS;

PROGNOSTIC FACTORS;

ONCOLOGY;

IRIDIUM 192;

ABDOMINAL HYSTERECTOMY; ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; BEAM THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; PELVIS LYMPHADENECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALPINGOOOPHORECTOMY; SCORING SYSTEM; SURVIVAL RATE; TOXICITY;

EID: 0035341738     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01571-6     Document Type: Article

References (95)

1. Cancer incidence and mortality in the European Union; Cancer registry data and estimates of national incidence for 1990
2. Carcinoma of the endometrium
3. The value of preoperative or postoperative treatment by radium for carcinoma of the uterine body
4. Operative treatment stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri
5. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus; Implications for therapy
6. Good outcome associated with standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium
7. Clinical stage I adenocarcinoma of the endometrium; Analysis of recurrences and the potential benefit of staging lymphadenectomy
8. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling; Report of a prospective trial
9. Surgery without radiotherapy for primary treatment of endometrial cancer
10. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus; Treatment comparisons
11. Post operative external irradiation and prognostic parameters in stage I endometrial carcinoma
12. A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma
13. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma
14. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer
15. The management of clinical stage I endometrial carcinoma
16. Preoperative whole pelvic external irradiation in stage I endometrial cancer
17. Preoperative radiation therapy in Stage I endometrial adenocarcinoma II. Final report of a clinical trial
18. Analysis of preoperative intracavitary cesium application versus postoperative external beam radiation in stage I endometrial carcinoma
19. Clinical stage I endometrial cancer; Results of adjuvant irradiation and patterns of failure
20. Preoperative radiotherapy and surgery for endometrial carcinoma; Prognostic significance of the sterilization of the specimen
21. Preoperative radiation therapy followed by extrafascial hysterectomy in patients with stage II endometrial carcinoma
22. Primary radiation therapy for endometrial carcinoma; A case controlled study
23. Postoperative adjuvant external-beam radiotherapy in surgical stage I endometrial carcinoma
24. Adjuvant external beam therapy for pathologic stage I and occult stage II endometrial carcinoma
25. Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma
26. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?
27. Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II
28. Combined surgery and radiation in endometrial carcinoma; An analysis of prognostic factors
29. Relationship between surgical-pathological risk factors and outcome in clinical stage I and stage II carcinoma of the endometrium; A Gynecol Oncol Group Study
30. Endometrial carcinoma, adjuvant radiotherapy tailored to prognosis factors
31. Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma; A clinical and histopathologic study of 175 patients
32. Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium
33. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications
34. Adjuvant whole abdominopelvis irradiation for 'high-risk' endometrial carcinoma
35. La plésiocuriethérapie des cancers du vagin par moulage plastique avec l'iridium 192 (préparation non radioactive)
36. Nonparametric estimation from incomplete observations
37. Lent Soma Scales for all anatomic sites
38. Chi-square with one degree of freedom; Extensions of the Mantel-Haenszel procedure
39. Regression models and life table
40. Tumor size in endometrial cancer
41. Low stage clear-cell carcinoma of the endometrium
42. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern
43. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?
44. Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma
45. Uterine papillary serous carcinoma. A clinical study
46. Uterine papillary serous carcinoma. Complete response to combination chemotherapy
47. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy
48. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium; Comparison of clinicopathologic features and survival
49. J. Facteurs pronostiques du cancer de l'endomètre; à propos de 206 cas traités à l'Institut Curie
50. Curiethérapie vaginale postopératoire des adénocarcinomes de l'endomètre à bas débit de dose
51. The justification for a surgical staging system in endometrial carcinoma
52. Pathological prognostic factors in a series of 137 stage I TNM/UICC endometrial carcinomas
53. Postoperative high dose-rate intra-vaginal brachytherapy combined with external irradiation for early stage endometrial cancer; A long-term follow-up
54. Postoperative radiation therapy for surgically staged endometrial cancer; Impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome
55. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation
56. Corpus; Epithelial tumors
57. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer
58. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer
59. The prognostic significance of vascular invasion by endometrial carcinoma
60. The importance of peritoneal cytology in endometrial carcinoma
61. Peritoneal washing cytology in gynecologic cancers; Long-term follow-up of 355 patients
62. Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology
63. Malignant peritoneal cytology as a prognostic indicator in stage I endometrial cancer
64. Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma
65. Aggressive stage I grade 1 endometrial carcinoma
66. A. Multivariate analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial cancer
67. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma
68. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki 67 proliferating cell nuclear antigen, and flow cytometric S-phase fraction
69. Angiogenesis in endometrial carcinoma
70. Endometrial carcinoma; Does the addition of intracavitary vault caesium to external beam therapy postoperatively result in improved control or increased morbidity?
71. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma; Multicentre randomised trials
72. Complications of pelvic lymphadenectomy in patients with endometrial adenocarcinoma
73. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer; Morbidity and mortality
74. Hysterectomy with extended surgical staging and radiotherapy versus hysterectomy alone and radiotherapy in stage I endometrial cancer; A comparison of complication rates
75. Adenocarcinoma of the endometrium; Survival comparisons of patients with and without pelvic node sampling
76. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma
77. Survival in patients with para-aortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus
78. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer
79. Postoperative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer
80. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma
81. Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse
82. Stage I corpus cancer; Is teletherapy necessary?
83. Aspects of surgery in ovarian and endometrial carcinoma
84. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer
85. Adjuvant progestagen therapy in the primary definitive treatment of endometrial cancer
86. A randomized trial of progestagens in the primary treatment of endometrial cancer
87. A randomized trial of adjuvant progestagen in early endometrial carcinoma
88. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II; A Gynecologic Oncology Group Study
89. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma; A Gynecologic Oncology Group (GOG) Study
90. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma